Genome editing represents one of the most significant recent advancements in molecular biology. CRISPR/Cas9 has been seen by many as cutting-edge (if you can pardon the pun) for its therapeutic application to genetic disease.
In 2024 however, the shortcomings of these first-generation CRISPR tools – namely in their targetability, specificity, and reliance on endogenous double-stranded break repair pathways – limit their functionalities and restrict their potential as the precise genome editing tools of the future.
The industry-leading 5th Genome Editing Therapeutics Summit (formerly known as CRISPR 2.0) will be convening in December, providing 120+ biopharma attendees with crucial drug development strategies and brand-new data from the latest real-world applications of both established and novel gene editing techniques.
Join us in December to:
- Access the latest data to stay ahead of cutting-edge editing and delivery technologies
- Tackle pressing drug development issues to speed up your path to the clinic
- Forge connections with leading drug developers, academics and vendors
Register your place today to be in the room for the gene editing field’s foremost drug development forum.